To validate the clinical importance of TROP2 in HNSCC, the gene expression was evaluated in 42 HNSCC patients, including 24 laryngeal and 18 hypopharyngeal carcinomas. The gene discussed is TACSTD2; the disease is hypopharyngeal carcinoma.